Yesterday

Does New Dravet Data for Zorevunersen Strengthen the Bull Case for Stoke Therapeutics (STOK)? Simply Wall St20:27 6-Dec-25

In the last 7 days

Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an… Biogen (Press Release)09:03 5-Dec-25

BIIB January 2026 Options Begin Trading Nasdaq11:09 4-Dec-25

Should New LEQEMBI Data and Subcutaneous Option Shift the Risk Profile for Biogen (BIIB) Investors? Simply Wall St08:14 4-Dec-25

Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in… Biogen (Press Release)18:11 3-Dec-25

New Data Presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025 Confirms Pharmacological Effect … Biogen (Press Release)16:41 2-Dec-25

Does Biogen’s Valuation Stack Up After Recent Alzheimer’s Regulatory Updates? Simply Wall St09:34 2-Dec-25

Pre-filled Syringe Presentation of Byooviz®, Samsung Bioepis' Biosimilar to Lucentis… Business Wire (Press Release)01:00 2-Dec-25

Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society… Business Wire (Press Release)07:38 1-Dec-25

Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting Biogen (Press Release)07:32 1-Dec-25

Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI(R)" for the… JCN Newswire03:03 1-Dec-25

A Look at Biogen's Valuation as It Expands Immunology Pipeline With Dayra Therapeutics Collaboration Simply Wall St00:43 30-Nov-25

In the last month

Nvidia, Microsoft, Apple, Zillow, Biogen: What brokers said this week Proactive Investors (Canada)15:19 28-Nov-25

Biogen, Eisai File In Japan To Make Leqembi A Weekly At-Home Alzheimer's Shot Benzinga13:37 28-Nov-25

Biogen shares could climb on Leqembi uptake – Jefferies Proactive Investors (US)09:45 28-Nov-25

Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer’s… Biogen (Press Release)19:31 27-Nov-25

Health Plans Defend Renewed Biogen MS Drug Scheme Suit Law36020:31 26-Nov-25

Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) IQLIK(TM) (lecanemabirmb)… JCN Newswire07:01 26-Nov-25

Biogen Inks Research Deal With Dayra to Boost Immunology Pipeline Zacks11:52 25-Nov-25

Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License… Biogen (Press Release)07:32 25-Nov-25

Why Biogen (BIIB) Is Up 7.4% After Announcing Dayra Immunology Collaboration and Pipeline Expansion Simply Wall St02:33 25-Nov-25

Biogen Joins The Macrocycle Melee With Dayra Tie-Up Scrip Pharma Intelligence16:30 24-Nov-25

Sandoz Launches Natalizumab Biosimilar JD Supra14:31 24-Nov-25

Why Is Biogen Stock Trading Higher After Semaglutide Alzheimer's Data? Benzinga11:25 24-Nov-25

Biogen to gain from Novo Nordisk Alzheimer’s failure, says Jefferies Investing.com10:02 24-Nov-25

Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a… Biogen (Press Release)07:34 24-Nov-25

Versant Ventures Announces Launch of Dayra Therapeutics With Foundational Biogen Partnership Business Wire (Press Release)07:30 24-Nov-25

Biogen Enters New Research Deal in Latest Immunology Push Bloomberg Law07:18 24-Nov-25

Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer’s Disease… Biogen (Press Release)07:32 20-Nov-25

Biogen and Eisai receive MHRA approval for updated dosing of early Alzheimer’s treatment PMLiVE08:23 19-Nov-25

Sandoz launches first biosimilar Tysabri in US pharmaphorum13:14 17-Nov-25

High-dose Spinraza inches closer to EU approval despite FDA setback Pharmaceutical Technology11:49 17-Nov-25

After delay, Sandoz's biosimilar Tyruko launches in US to pressure Biogen's blockbuster MS med… FiercePharma11:24 17-Nov-25

"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease… JCN Newswire10:04 17-Nov-25

Biogen Stock: Is Wall Street Bullish or Bearish? Barchart09:00 17-Nov-25

Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of… Biogen (Press Release)07:32 17-Nov-25

High dose nusinersen regimen receives positive CHMP opinion PharmaTimes07:08 17-Nov-25

High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy Biogen (Press Release)06:01 17-Nov-25

Biogen acquires Alcyone to boost CNS drug delivery Verdict Medical Devices05:53 17-Nov-25

Biogen Completes Acquisition of Alcyone Therapeutics Biogen (Press Release)16:14 14-Nov-25

Mhra approves Leqembi IV maintenance as additional Alzheimer’s option European Pharmaceutical Review09:05 14-Nov-25

Eisai and Biogen report Leqembi’s MHRA approval for Alzheimer’s Pharmaceutical Technology04:08 14-Nov-25

“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in the United… Biogen (Press Release)18:39 13-Nov-25

Antibody-Mediated Rejection Market Set to Expand Significantly During the Forecast Period… PR Newswire (Press Release)17:31 11-Nov-25

Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 257: Biogen’s $2B Investment in North… JD Supra16:21 11-Nov-25

Is Biogen Worth a Fresh Look After Major Drug Approvals in 2025? Simply Wall St11:44 9-Nov-25

Phase 3 trial shows Alzheimer’s drug slows progression of disease Longevity Technology13:34 7-Nov-25

Braveheart, AAVantgarde rounds head recent biofinancings pharmaphorum08:04 7-Nov-25

Biogen Pharmachem Industries reports standalone net loss of Rs 0.49 crore in the September 2025 quarter The Business Standard07:02 7-Nov-25

view more headlines

6 Dec 20:27

About our Biogen News

Biogen is an American multinational biotechnology company that specialises in treatment of neurological diseases.

Biogen

Latest News

About our Biogen News

Biotech Top Stories

Business Top Stories